Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Assumed to be non-addictive with low abuse potential based on similarity to LSD. Animal self-administration studies with LSD (a model predictive of abuse liability) have consistently failed, indicating the pharmacology does not support initiation or maintenance of dependence.
Virtually no withdrawal syndrome is expected when use is stopped, based on comparison to LSD which produces no physical dependence.
No known toxic dose has been established. Based on its similarity to LSD, 1B-LSD is assumed to be physiologically well-tolerated with extremely low toxicity relative to dose.
1B-LSD may act as a trigger for psychotic episodes in individuals with underlying mental disorders or a personal or family history of mental illness. Higher doses increase the risk of adverse psychological reactions including delusions. Those predisposed to mental illness are advised not to use this substance outside of supervised medical settings.
Seizure risk is largely extrapolated from rare reports associated with LSD use. Seizures are thought to mainly affect those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
1B-LSD emerged on the online research chemical market in August 2016, following a pattern common among novel lysergamide derivatives designed to occupy legal grey areas in jurisdictions where LSD itself is controlled. The identity of the original synthesizer remains unknown, and notably, no…
Not scheduled under the UN Convention on Psychotropic Substances
While not technically illegal by name, 1B-LSD may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD, rendering it illegal to supply for human consumption.
Controlled under the Pharmaceutical Affairs Law. Both possession and sale are prohibited.
Specifically named on the national list of controlled substances since June 5, 2019.
Prohibited as of January 26, 2016, following its emergence as a designer drug. Sweden's public health agency further recommended classifying it as a hazardous substance on June 24, 2019.
Prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and importation are criminal offenses.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to penalty.
Although not officially scheduled by name, 1B-LSD is controlled as a structural analogue of LSD pursuant to an amendment enacted on June 1, 2015.
Prohibited under Singapore's controlled substances legislation.
Considered a controlled substance as a defined derivative of lysergic acid under Verzeichnis E, point 263. Remains legal when used exclusively for scientific or industrial purposes.
Not explicitly listed as a controlled substance. However, as a prodrug that metabolizes to LSD, possession and sale may be prosecutable under the Federal Analogue Act when intended for human consumption.
15 sources cited
